Publications by authors named "Shunsuke Hagihara"
Article Synopsis
- Nivolumab combined with chemotherapy has become the standard treatment for advanced HER2-negative gastric cancer, with a focus on understanding its long-term effects through clinical trials.
- In the ATTRACTON-4 trial, conducted across Japan, South Korea, and Taiwan, patients were assigned to either nivolumab or a placebo alongside common chemotherapy regimens, with the primary goals being progression-free survival and overall survival.
- After three years, the nivolumab group showed longer progression-free survival but similar overall survival compared to the placebo group, with a significant majority of patients who responded completely to treatment remaining alive, indicating its effective and safe use in this setting.
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Gastroenterol Hepatol
August 2024
Article Synopsis
- In Asia, adjuvant chemotherapy combined with nivolumab post-gastrectomy is being assessed for effectiveness and safety in treating pathological stage III gastric or gastro-oesophageal junction cancer.
- The ATTRACTION-5 trial involved a randomized, double-blind study across 96 hospitals in East Asia, enrolling patients aged 20-80 with confirmed stage IIIA-C cancer following specific surgeries.
- Patients were divided into two groups to receive either nivolumab with chemotherapy or a placebo with chemotherapy, with the main focus on measuring relapse-free survival and analyzing safety data.
Background: The additive or synergistic sustained antitumour effect of immune checkpoint inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. We investigated the efficacy of nivolumab plus oxaliplatin-based chemotherapy versus placebo plus oxaliplatin-based chemotherapy as first-line therapy for patients with HER2-negative, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer.
Methods: We did a randomised, multicentre, double-blind, placebo-controlled, phase 2-3 trial (ATTRACTION-4) at 130 centres (hospitals, cancer centres, and medical centres) across Japan, South Korea, and Taiwan.
Background: An open-label, non-comparative study assessed the efficacy and safety of nivolumab in Japanese patients with first recurrence glioblastoma.
Methods: Patients with first recurrence of histologically confirmed World Health Organization Grade IV glioma, after treatment with temozolomide and radiotherapy, received nivolumab 3 mg/kg every 2 weeks until confirmed disease progression (Response Assessment in Neuro-Oncology criteria) or toxicity. Primary endpoint was 1-year overall survival rate assessed by Bayesian approach.
Background: The treatment of pemphigus is based on systemic corticosteroid use and adjuvant therapies, but some patients are resistant to conventional therapy. Tirabrutinib is a highly selective oral Bruton's tyrosine kinase inhibitor that may be clinically effective in treating pemphigus by suppressing B-cell signaling.
Objective: We investigated the efficacy and safety of tirabrutinib in patients with refractory pemphigus.